Back to Search
DR. JONATHAN AMATRUDA M.D.
M.D.
Nephrology Physician
NPI: 1912387713IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
A155033(CA)
Nephrology PhysicianPrimary
Internal Medicine — Nephrology
Code: 207RN0300X
A155033(CA)MD28202(ME)
Education
UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE
Class of 2015
Research & Publications (20)
Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.
PMID 19232032·Curr Med Res Opin·2009
4-observational
Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer.
PMID 19125156·Nat Chem Biol·2009
8-other
Structure-activity relationship studies of small-molecule inhibitors of Wnt response.
PMID 19410457·Bioorg Med Chem Lett·2009
7-preclinical
Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea.
PMID 19097665·Diabetes Res Clin Pract·2009
2-rct
Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus.
PMID 19253204·Horm Metab Res·2009
3-trial
Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis.
PMID 18954434·BMC Endocr Disord·2008
8-other
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.
PMID 18518892·Diabetes Obes Metab·2008
4-observational
Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3.
PMID 18510930·Cell·2008
7-preclinical
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.
PMID 18194595·Curr Med Res Opin·2008
4-observational
The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.
PMID 18177726·Cell Metab·2008
2-rct
Indanylacetic acids as PPAR-delta activator insulin sensitizers.
PMID 17601734·Bioorg Med Chem Lett·2007
8-other
A mutation in separase causes genome instability and increased susceptibility to epithelial cancer.
PMID 17210788·Genes Dev·2007
7-preclinical
Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults.
PMID 17341568·J Clin Endocrinol Metab·2007
4-observational
Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss.
PMID 17426325·Obesity (Silver Spring)·2007
4-observational
NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine.
PMID 17712121·Obesity (Silver Spring)·2007
4-observational
The INT6 cancer gene and MEK signaling pathways converge during zebrafish development.
PMID 17895999·PLoS One·2007
7-preclinical
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults.
PMID 17011500·Cell Metab·2006
4-observational
Small molecules that delay S phase suppress a zebrafish bmyb mutant.
PMID 16372403·Nat Chem Biol·2005
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1600 CONGRESS ST STE B
PORTLAND, ME 04102 - Phone
- (207) 774-5222
Quick Facts
- NPI
- 1912387713
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 11
- Publications
- 20
Are you this provider?
Claim Your Profile